Malignancy induced by the BCR-ABL1 fusion gene accounts for more than 90% of the incidence of CML.20 In addition to CML, approximately 25–30% of adult B-cell ALL cases are BCR-ABL1-positive,21 and 2–10% of children’s ALL cases.20 The ubiquitously expressed non-receptor tyrosine kinase ABL1 plays a vital role in controlling cell proliferation and survival. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.